STOCK TITAN

Atreca Inc - BCEL STOCK NEWS

Welcome to our dedicated news page for Atreca (Ticker: BCEL), a resource for investors and traders seeking the latest updates and insights on Atreca.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Atreca's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Atreca's position in the market.

Rhea-AI Summary
Atreca, Inc. (NASDAQ: BCEL) announced a definitive asset purchase agreement with Immunome, Inc. (Nasdaq: IMNM) to sell a collection of antibody-related assets and materials. The agreement includes an upfront payment of $5.5 million and up to $7.0 million in clinical development milestones, totaling up to $12.5 million. Atreca's President and CEO, John Orwin, expressed optimism about the potential of the tumor-targeting antibodies discovered by Atreca, including APN-497444, in oncology. The asset sale is subject to approval from Atreca stockholders holding a majority of the outstanding shares of Atreca’s Class A common stock entitled to vote.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-22.73%
Tags
none
-
Rhea-AI Summary
Immunome, Inc. (IMNM) Acquires Antibody-Related Assets and Materials from Atreca, Inc. (BCEL)
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-22.73%
Tags
-
Rhea-AI Summary
Atreca, Inc. (NASDAQ: BCEL) Reports Q3 2023 Financial Results and Implements Workforce Reduction of 40%
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-23.17%
Tags
Rhea-AI Summary
Atreca terminates lease agreement to lower expenses, saving $13 million annually. CFO departs, CEO assumes financial officer role. Amended lease agreement with Alexandria Real Estate Equities for $5 million. Cash runway extended through Q1 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.21%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-36.52%
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-14.82%
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.68%
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.14%
Tags
conferences
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-11.54%
Tags
Atreca Inc

Nasdaq:BCEL

BCEL Rankings

BCEL Stock Data

3.01M
28.77M
2.68%
24.47%
0.69%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
US
South San Francisco

About BCEL

atreca is a biotechnology company that develops novel therapeutics through a deep understanding of the human immune response, with a focus on innovative novel cancer immunotherapeutics. with its immune repertoire capture™ (irc™) technology, atreca has an unparalleled insight into how cancer patients’ immune responses can drive better clinical outcomes. atreca was founded by scientists, industry experts, and investors who share the vision that unlocking the immune response of today’s patients is the key to creating a new generation of therapies. atreca is looking for talented, entrepreneurial people who are dedicated to making a positive impact on human health. if you are interested in becoming part of the atreca team, our open positions can be found at: http://www.atreca.com/careers/